Cargando…
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
Niraparib (Zejula™) is a PARP inhibitor which is approved for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy. In a placebo-controlled phase III trial in patients with newly diagnosed advanced ovarian cancer, niraparib signifi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613118/ https://www.ncbi.nlm.nih.gov/pubmed/34635996 http://dx.doi.org/10.1007/s11523-021-00841-2 |